2-Ethyl-4-n-propylimidazol | 37455-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Ethyl-4-n-propylimidazol
• 英文别名: 2-ethyl-4-propyl-1(3)H-imidazole；2-ethyl-4-propyl-1H-imidazole；2-ethyl-5-propyl-1H-imidazole
• CAS: 37455-54-2
• 化学式: C₈H₁₄N₂
• mdl: MFCD19219188
• 分子量: 138.213
• InChiKey: LSXICBAPPWKECV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-ethyl-4-propyl-1-trityl-1H-imidazole 在 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 8.0h， 以96%的产率得到2-Ethyl-4-n-propylimidazol
  参考文献：
  名称：

  [EN] TRIAZINE COMPOUNDS AS KINASE INHIBITORS
  [FR] COMPOSÉS DE TRIAZINE COMME INHIBITEURS DE LA KINASE

  摘要：

  本发明涉及作为激酶抑制剂有用的三嗪化合物。更具体地说，本发明涉及吗啡啶取代的三嗪，其制备方法，含有这些化合物的药物组合物以及这些化合物在治疗增生性疾病中的用途。这些化合物可能作为药物用于治疗多种增生性疾病，包括肿瘤和癌症以及与mTOR激酶或PI3激酶相关的其他疾病或病况。这些化合物的结构如下（I）。

  公开号：

  WO2009093981A1

文献信息

• Complexes Of Imidazole Ligands
  申请人：Norman John Anthony Thomas

  公开号：US20120121806A1

  公开（公告）日：2012-05-17

  Metal imidazolate complexes are described where imidazoles ligands functionalized with bulky groups and their anionic counterpart, i.e., imidazolates are described. Compounds comprising one or more such polyalkylated imidazolate anions coordinated to a metal or more than one metal, selected from the group consisting of alkali metals, transition metals, lanthanide metals, actinide metals, main group metals, including the chalcogenides, are contemplated. Alternatively, multiple different imidazole anions, in addition to other different anions, can be coordinated to metals to make new complexes. The synthesis of novel compounds and their use to form thin metal containing films is also contemplated.

  本文描述了具有大体积基团的咪唑配体及其阴离子对应物即咪唑酸盐的金属咪唑酸盐络合物。本文考虑了由一种或多种这种多烷基化咪唑酸盐阴离子与一种或多种金属（包括碱金属、过渡金属、稀土金属、锕系金属、主族金属和硫属化物）配位而成的化合物。此外，还可以将多种不同的咪唑酸盐阴离子与其他不同的阴离子配位到金属上，以制备新的络合物。本文还考虑了合成新化合物并将其用于形成含金属薄膜的用途。
• Amine composition useful for making polyurethane foam
  申请人：Evonik Operations GmbH

  公开号：US11021561B2

  公开（公告）日：2021-06-01

  A catalyst composition for making polyurethane foam, the catalyst composition including a compound having a general formula R1R2R3N, wherein each of R1, R2 and R3 are independently selected from the group consisting of: a compound according to formula (I): wherein n=1 to 5; and R4, R5 and R6 are each independently hydrogen, methyl, ethyl and propyl groups; hydrogen, a C1-C6 alkyl group compound, a C1-C6 cycloalkyl group compound, a C1-C6 alkenyl group compound, a C1-C6 alkynyl group compound, a C1-C6 aryl group compound, and a C1-C6 aralkyl group compound, each group being substituted or unsubstituted; wherein at least one of R1, R2 and R3 is a compound according to formula (I). A polyurethane composition and method for forming a polyurethane foam are also disclosed.

  一种用于制造聚氨酯泡沫的催化剂组合物，该催化剂组合物包括通式为 R1R2R3N 的化合物，其中 R1、R2 和 R3 各自独立地选自由以下各项组成的组： 符合式 (I) 的化合物： 其中 n=1 至 5；以及 R4、R5 和 R6 各自独立地为氢、甲基、乙基和丙基；氢、C1-C6 烷基化合物、C1-C6 环烷基化合物、C1-C6 烯基化合物、C1-C6 炔基化合物、C1-C6 芳基化合物和 C1-C6 芳烷基化合物，每个基团被取代或未被取代；其中 R1、R2 和 R3 中至少有一个是根据式 (I) 的化合物。本发明还公开了一种聚氨酯组合物和形成聚氨酯泡沫的方法。
• POLYMERIC COMPOSITION COMPRISING METAL ALKOXIDE CONDENSATION PRODUCT, ORGANIC SILANE COMPOUND AND BORON COMPOUND
  申请人：Nitto Boseki CO., LTD.

  公开号：EP2072582B1

  公开（公告）日：2011-12-07
• AMINE COMPOSITION USEFUL FOR MAKING POLYURETHANE FOAM
  申请人：Evonik Degussa GmbH

  公开号：EP3481878A1

  公开（公告）日：2019-05-15
• EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF
  申请人：XIAMEN SINOPEG BIOTECH CO., LTD

  公开号：US20180214561A1

  公开（公告）日：2018-08-02

  Disclosed are an eight-arm polyethylene glycol (PEG) derivative (formula I), production method therefor and modified bio-related substance thereby. Wherein, one tetravalent group U together with four trivalent groups E c form a highly symmetrical octavalent group CORE 0 ; L c connects the octavalent group to eight PEG chains having polydispersity or monodispersity and having n 1 to n 8 as the degree of polymerization thereof; the terminal of one PEG chain is connected to at least one functional group F (k≥1); said PEG chain and F therebetween can be directly connected (g=0) or be indirectly connected via a linking group L 0 to a terminal end-branching group G (g=1); the latter provides more reactive sites for binding more drug molecules and increases the drug loading. The eight-arm polyethylene glycol derivative has a centrosymmetric or approximately centrosymmetric structure, and leads to more precise control of the molecular weight in large-scale production and much narrower distribution of molecular weight for products. The modified bio-related substance thereby has a more uniform and controllable performance.